COVID-19

The fifth update from the American College of Rheumatology supports fourth doses of the vaccine for high-risk rheumatic disease patients.

Investigators observed significant increases in the rate of encounters with children and adolescents with autism spectrum disorder, as well as those with anxiety and depression.

Investigators noted that clinically relevant risks could not be excluded with certainty despite not seeing a statistically significant increase in corresponding risks for more rare and severe thrombotic outcomes.

The application for NVX-CoV2373 is supported by promising data from 2 multinational trials conducted prior to the spread of the Omicron variant.

The approval of the Spikevax vaccine was based on safety and efficacy data approximately 6 months after the second dose.

Though continuous positive airway pressure and high-flow nasal oxygen have both been recommended for acute hypoxemic respiratory failure in patients infected with the COVID-19 virus, the effectiveness and safety of these strategies were uncertain.

Investigators say that reducing COVID-19 hospitalizations among these groups will require partnerships among homeless services, correctional facilities and agencies, health care professionals, and public health agencies.

New findings from CDC data show three-fourths of all myocarditis cases observed in the first 8 months of COVID-19 vaccination occurred in persons 30 years and younger.

Analysis of 2 national surveys suggest a more than two-fold greater likelihood of depressed Americans endorsing a false fact about COVID-19 vaccines than others.

Despite the assumption of vaccine hesitancy among Black people in the US, the present study found rapid reductions in COVID-19 vaccine hesitancy among Black individuals in the US.

Immunomodulators, incomplete vaccination, and non-mRNA vaccination were associated with a higher risk of adverse events for patients with IBD.

Patients with asthma were at increased risk of hospitalization and ICU admission or death, prompting investigators to suggest these patients be considered a priority group for booster COVID-19 vaccines.

Julia Haas, PhD, discusses her team's recent findings that one-third of patients in COVID-19 vaccine trials reported side effects after receiving a placebo dose.

New data show "nocebo responses" are frequent in COVID-19 vaccine studies—which may drive recipients' expectation of side effects.

The Prevalence of inflammatory bowel disease is highest in the Western world.

After conducting and extensive literary review on all eligible data regarding COVID-19 in patients with sickle cell disease or trait, experts discuss what is known and what needs to be better understood about the pandemic's effect on this population.

Investigators conducted an extensive literature review on clinical COVID-19 outcomes in patients with SCD or SCT to better navigate treatment during the pandemic.

Additionally, no increase in incidences of stroke or pulmonary embolism were seen 14 days after the 2 vaccine doses.

Burnout problems persisted prior to the COVID-19 pandemic, but have been made worse since the beginning of the pandemic.

The FDA moved to shorten the time between the second and third vaccine dose from 6 months to 5 months for recipients of Pfizer-BioNTech.

GI symptoms manifest in children with COVID-19 more than they do in adult patients.

Allergists discuss the differing opinions of allergies and optimizing patient care during the COVID-19 pandemic.

Of the SCD patients who contracted COVID-19, 49% of them visited the Grady Comprehensive Sickle Cell center because of a vaso-occlusive event.

Patients with SCD were not at an increased risk of death or disease complications.

The data shows booster shots offer particularly strong protection against the variant.

Among vaccinated individuals, results show a 90% lower mortality rate due to COVID-19 in the group that received a booster compared with those who did not.

In a recent clinical trial, Evusheld recipients at increased risk of severe COVID-19 infection saw a 77% reduced risk of developing COVID-19.

Investigators detail the clinical criteria of the condition and speak to the safety of the COVID-19 vaccine for this patient population.

Promising results show that high-flow oxygen therapy is more effective in treating patients with severe COVID-19 than conventional methods like invasive mechanical ventilation.